2-氨基-1-乙氧基-3,4-二氧代-1-环丁烯 | 29950-12-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氨基-1-乙氧基-3,4-二氧代-1-环丁烯
• 英文名称: 3-amino-4-ethoxy-3-cyclobutene-1,2-dione
• 英文别名: 3-amino-4-ethoxycyclobut-3-ene-1,2-dione；2-amino-1-ethoxy-3,4-dioxo-1-cyclobutene
• CAS: 29950-12-7
• 化学式: C₆H₇NO₃
• mdl: MFCD18817814
• 分子量: 141.126
• InChiKey: RMMBULJTXVBMPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-1-乙氧基-3,4-二氧代-1-环丁烯 、 4-氨基丁酸 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 Sodium;4-[(2-amino-3,4-dioxocyclobuten-1-yl)amino]butanoate
  参考文献：
  名称：

  Bioisosteric replacement of the .alpha.-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists

  摘要：

  In this report, a novel bioisostere of the alpha-amino acid 3,4-diamino-3-cyclobutene-1,2-dione, has been incorporated into a series of compounds which are NMDA antagonists. These compounds, which are achiral and easily prepared, demonstrated good affinity at the NMDA receptor by their ability to displace [H-3]CPP binding in vitro. In particular, the phosphonic acid 24 provided protection against NMDA-induced lethality in mice equivalent to 2-amino-7-phosphonoheptanoic acid (5). This was considered an encouraging result in lieu of the fact that 24, like 5, lacks the conformational rigidity of the more potent NMDA antagonists. In addition, analogs that incorporate the 1,2,4-oxadiazolidine-3,5-dione heterocycle of quisqualic acid and the unsaturation of kainic acid were prepared to explore selectivity at the non-NMDA receptor subtypes.

  DOI：

  10.1021/jm00103a010
• 作为产物：
  描述：

  方酸二乙酯 在 氨 作用下， 以 乙醇 为溶剂， 以96%的产率得到2-氨基-1-乙氧基-3,4-二氧代-1-环丁烯
  参考文献：
  名称：

  Responsive MR-imaging probes for N-methyl-d-aspartate receptors and direct visualisation of the cell-surface receptors by optical microscopy

  摘要：

  一系列基于已知的竞争性N-甲基-D-天冬氨酸（NMDA）拮抗剂3,4-二氨基-3-环丁烯-1,2-二酮的NMDA受体靶向磁共振成像（MRI）造影剂已被开发出来。这些造影剂作为响应性MR成像探针的用途已在体外进行了评估，其中两种造影剂在与神经细胞系模型共育后显示出170–176%的弛豫率增强效果。一种含有生物素部分的前体化合物衍生物被制备出来，并通过共聚焦显微镜演示了其与NMDA细胞表面受体结合的特异性和可逆性。

  DOI：

  10.1039/c3sc50903f

文献信息

• [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2019243550A1

  公开（公告）日：2019-12-26

  Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

  提供了公式（I）的噻吩衍生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途，如过敏、1型超敏反应或家族性鼻窦炎。
• APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20200157095A1

  公开（公告）日：2020-05-21

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了化合物的结构式(I)，以及其药学上可接受的盐和酯： 这些化合物抑制凋亡信号调节激酶1（ASK-1），与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病相关。本发明还涉及包含上述化合物的药物组合物，用于治疗患有ASK-1相关疾病的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明具体涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎病（NASH）。
• MACROLIDE DERIVATIVES
  申请人：Kashimura Masato

  公开号：US20090076253A1

  公开（公告）日：2009-03-19

  Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

  由公式（I）和公式（IV）表示的化合物具有抑制MMP-9产生的活性，因此，它们可用作药物代理，其副作用比传统的MMP酶活性抑制剂少，作为预防和治疗肿瘤血管生成、慢性类风湿关节炎、经皮冠状动脉病变介入治疗后的血管内膜增厚、血管动脉粥样硬化、出血性中风、急性心肌梗死、慢性心力衰竭、动脉瘤、肺癌转移、成人呼吸窘迫综合征、哮喘、间质性肺纤维化、慢性鼻窦炎、支气管炎或慢性阻塞性肺疾病（COPD）的药物。
• N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20200095239A1

  公开（公告）日：2020-03-26

  The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

  本发明涉及式(IA和1B)所示的N-取代-二氧环丁烯基氨基-3-羟基-吡咯烷酰胺化合物或其药用可接受盐或水合物，这些化合物抑制CC趋化因子受体6 (CCR6)，包含这些化合物的药物组合物，以及使用这些化合物来治疗或预防通过抑制CCR6而改善的疾病、状况或失调。
• [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
  申请人：American Home Products Corporation

  公开号：US05168103A1

  公开（公告）日：1992-12-01

  A compound of the formula: ##STR1## in which R.sup.1 is hydrogen, alkyl or phenylalkyl; R.sup.2 is hydrogen, alkyl, alkenyl or phenylalkyl; or R.sup.1 and R.sup.2 taken together are --Ch.sub.2 CH.sub.2 --, --CH.sub.2 C(R.sup.6)(R.sup.7)CH.sub.2 --or --CH.sub.2 C(R.sup.8)(R.sup.9)--C(R.sup.10)(R.sup.11)CH.sub.2 --, where R.sup.6, R.sup.8 and R.sup.10 are, independently, hydrogen, alkyl of 1 to 6 carbon atoms or hydroxyl and R.sup.7, R.sup.9 and R.sup.11 are, independently, hydrogen or alkyl of 1 to 6 carbon atoms; A is alkylene or alkenylene; X is CO.sub.2 R.sup.3 in which R.sup.3 is hydrogen or alkyl, P(O)(OR.sup.4)(OR.sup.5) in which R.sup.4 and R.sup.5 are, independently, hydrogen or alkyl, 3,5-dioxo-1,2,4-oxadiazolindin-2-yl or 5-tetrazolyl; or a pharmaceutically acceptable salt thereof are useful as neuroprotectants.

  公式为：##STR1## 其中 R.sup.1 是氢、烷基或苯基烷基；R.sup.2 是氢、烷基、烯基或苯基烷基；或者 R.sup.1 和 R.sup.2 一起是 --Ch.sub.2 CH.sub.2 --，--CH.sub.2 C(R.sup.6)(R.sup.7)CH.sub.2 -- 或 --CH.sub.2 C(R.sup.8)(R.sup.9)--C(R.sup.10)(R.sup.11)CH.sub.2 --，其中 R.sup.6、R.sup.8 和 R.sup.10 独立地是氢、1 到 6 个碳原子的烷基或羟基，而 R.sup.7、R.sup.9 和 R.sup.11 独立地是氢或 1 到 6 个碳原子的烷基；A 是烷基或烯基；X 是 CO.sub.2 R.sup.3，其中 R.sup.3 是氢或烷基，P(O)(OR.sup.4)(OR.sup.5)，其中 R.sup.4 和 R.sup.5 独立地是氢或烷基，3,5-二氧代-1,2,4-噁二唑啉-2-基或 5-四唑基；或其药学上可接受的盐对神经保护剂具有用处。